Navigation Links
Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
Date:8/14/2008

ing for making related regulatory filings; our ability to estimate accurately the amount of cash to be used to fund operations over the next 12 months, our ability to obtain future financing and fund the product development of our pipeline; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its annual report on Form 10-K for the period ended June 30, 2007 and its subsequently filed quarterly reports on Form 10-Q. Forward-looking statements contained in this announcement are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

---FINANCIALS ATTACHED---

Pharmacyclics, Inc.

(a development stage enterprise)

Condensed Statements of Operations

(unaudited) (in thousands, except per share data)

Three Months Twelve Months

Ended June 30, Ended June 30,

2008 2007 2008 2007

Grant revenue $-- $107 $-- $126

Operating expenses:

Research and development 3,3
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
2. Pharmacyclics Announces It Received Nasdaq Notification
3. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014   Synthetic Biologics, Inc. ... therapies for serious infections and diseases, with ... announced positive topline safety and tolerability results ... SYN-004, the Company,s investigational oral beta-lactamase enzyme ... (C. difficile) infection, antibiotic-associated diarrhea and ...
(Date:12/22/2014)... N.C. , Dec. 22, 2014  Alternative ... announced that it has signed a letter of ... that has developed and patented a nanotechnology-based development ... diagnostics products that enable rapid on-site collection and ... use/abuse and health issues in an immediate, non-invasive ...
(Date:12/22/2014)... Calif. , Dec. 22, 2014  ( www.competitivehealth.com ... CoPatient, an online medical bill review and advocacy service, ... in the FREE WellCard Savings discount health services marketplace. ... bill that was more than they expected to pay. ... reduce health care costs, WellCard Savings is pleased to ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... , , SOUTH SAN ... SNSS ) reported today that it received a letter, dated September ... NASDAQ Stock Market notifying Sunesis that it does not comply with ... NASDAQ Capital Market set forth in NASDAQ Listing Rule 5550(a)(2). The ...
... , SAN DIEGO, Sept. 18, 2009 ... today that the company is scheduled to present at the UBS ... Eastern Time (12:30 p.m. Pacific Time) at the Grand Hyatt Hotel ... Officer, is scheduled to provide an overview of the company, including ...
... PRINCETON, N.J., Sept. 18 Covance Inc. (NYSE: ... Global Life Sciences Conference on Monday, September 21, 2009 at 10:00 ... presentation at www.covance.com . In order to ... early. , , Covance, with headquarters in Princeton, ...
Cached Biology Technology:Sunesis Pharmaceuticals Receives NASDAQ Notification 2Sunesis Pharmaceuticals Receives NASDAQ Notification 3Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference 2Arena Pharmaceuticals to Present at the UBS Global Life Sciences Conference 3
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Valencell, a ... it is seeing a staggering demand from its licensees ... the Company revealed, is not solely coming from fitness ... as well. "A wearable is only as ... result, accuracy is the ultimate driver in long-term mass ...
(Date:12/10/2014)... Research and Markets ( http://www.researchandmarkets.com/research/xclcvw/biometrics_market ... "Biometrics Market in Japan 2014-2018" report to ... The integration of biometrics and ... and upgradation of the driver,s license is one ... Besides the aforementioned projects, biometrics is being used ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... hadrosaur (duck-billed) dinosaur the oldest duck-billed dinosaur known ... who expect the discovery to shed new light on ... gagslarsoni , the name given to the new dinosaur, ... to later duck-billed relatives. Acristavus means "non-crested ...
... PASADENA, Calif.Artificial intelligence has been the inspiration for countless ... countless scientists and engineers. Researchers at the California Institute ... toward creating artificial intelligencenot in a robot or a ... are the first to have made an artificial neural ...
... SALT LAKE CITY A team of researchers from the ... mouse model of focal dermal hypoplasia, a rare human birth ... This animal model not only provides insight into studying the ... novel way to study a signaling pathway that is crucial ...
Cached Biology News:New duck-billed dinosaur gives scientists clues to evolution of head ornamentation and provinciality 2Caltech researchers create the first artificial neural network out of DNA 2Caltech researchers create the first artificial neural network out of DNA 3Caltech researchers create the first artificial neural network out of DNA 4Animal model sheds light on rare genetic disorder, signaling pathway 2
... Radiolabeled Ligands\n\nReceptor-related research has long been enabled ... ligands selected to keep pace with new ... products and services for receptor research and ... If you do not find exactly what ...
... taken from the SMZ line is a Greenough ... and testing. It is available with a choice ... a space-saving compact base (N2GG). This microscope can ... a projector all at the same time giving ...
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... UNIchip AV-400 contains 400 unique human ... glass slide. The proteins, all intracellular ... classification, are arrayed in quadruplicate for ... a specific chip layout guarantee high ...
Biology Products: